Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company’s lead cancer immunotherapy program SOUTH SAN FRANSCISCO, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the U.S. Food and Drug Admini ...

ORLANDO, Fla., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL), a leader in the alternative asset management space, today announced its participation in two upcoming investor conferences in September 2025. The Company will attend the B. Riley Securities 8th Annual Consumer & TMT Conference on September 10, 2025, at the Sofitel New York in New York City. Chief Operating Officer Elena Plesco and Senior Vice President of Investor Relations and Corpora ...

CORNELIUS, N.C., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Alpha Modus, Corp., a subsidiary of Alpha Modus Holdings Inc. (NASDAQ: AMOD) (“Alpha Modus” or the “Company”), today announced that it has filed a patent infringement lawsuit against Creative Realities, Inc. (“CRI”) in the United States District Court for the Eastern District of Texas, Marshall Division. The complaint asserts infringement of five of Alpha Modus’s foundational patents: U.S. Patent Nos. 10,360,571; 10,853,825; 10,977,672; 11,042,890; and 11, ...

Core Viewpoint - Hurco Companies, Inc. reported a net loss of $3.69 million for Q3 2025, an improvement from a net loss of $9.60 million in Q3 2024, indicating progress in financial performance despite ongoing challenges in the market [1][18]. Financial Performance - For Q3 2025, Hurco's sales and service fees reached $45.81 million, a 7% increase from $42.65 million in Q3 2024, aided by a favorable currency impact of $1.38 million [2][18]. - The gross profit for Q3 2025 was $9.11 million, representing 20% of sales, compared to $7.84 million or 18% of sales in the same quarter of the previous year [10][18]. - Selling, general, and administrative expenses for Q3 2025 were $10.76 million, or 23% of sales, down from 24% in Q3 2024, reflecting cost management efforts [11][12]. Geographic Sales Breakdown - Sales in the Americas increased by 10% to $16.90 million in Q3 2025, while sales in Europe remained flat at $24.17 million, and Asia Pacific saw a significant increase of 48% to $4.74 million [3][4][5]. - For the nine months of fiscal year 2025, total sales were $133.09 million, a slight increase of less than 1% compared to the same period in 2024 [2][3]. Orders and Demand - Total orders for Q3 2025 were $40.99 million, a decrease of 22% from $52.82 million in Q3 2024, with notable declines in orders from the Americas and Europe [6][7][8]. - Orders in the Americas decreased by 12% in Q3 2025, primarily due to reduced demand for Hurco and Milltronics machines [7][8]. Cash Position and Capital Allocation - As of July 31, 2025, cash and cash equivalents totaled $44.49 million, an increase from $33.33 million at the end of October 2024, indicating a strengthened cash position [14][18]. - The company has a share repurchase program with $19.68 million available for future repurchases, reflecting a commitment to returning value to shareholders [15][16]. Management Commentary - The CEO expressed optimism about the company's progress, highlighting improved gross profit and reduced operating costs, while acknowledging cautious capital purchase decisions due to macroeconomic uncertainty [3][16].

NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced a joint presentation at the H.C. Wainwright 27th Annual Global Investment Conference (https://hcwevents.com/annualconferen ...

Company Overview - FST Corp. is a leading manufacturer and marketer of steel and graphite golf shafts, providing various golf-related services [5] - Founded in 1989, the company sells golf club shafts and other items to golf equipment brands, OEMs, distributors, and consumers through KBS Golf Experience retail outlets [5] - The KBS brand is utilized by golfers at all levels, including many professional players in the PGA and other major golf associations [5] - FST Corp. has established a vertically integrated business model that creates significant competitive advantages over peer brands [5] - The company is currently positioned for expansion into the PRC and other under-tapped golf shaft markets [5] Event Participation - FST Corp. will participate in the 27th Annual H.C. Wainwright Global Investment Conference from September 8 to September 10, 2025 [1] - Sebastian Tadla, CFO, and Kathee Lin, Head of Investor Relations, will deliver a company presentation and be available for one-on-one investor meetings during the event [2] - The company's presentation is scheduled for September 8, 2025, from 2:30 PM to 3:00 PM in the Winslow Room, 5th Floor [8]

– 17 abstracts accepted, including one oral presentation – – Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates – – REFRESH study also highlights efficacy in those who were new to oxybate or returning to oxybate after discontinuing twice-nightly oxybate – DUBLIN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today a ...

ROCKAWAY, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the departure of Peter Cuneo from the Board of Directors and that Thomas J. Errico, MD, has been elected to succeed Mr. Cuneo as Chairman of the Board, effective September 2, 2025. Mr. Cuneo will continue as a strategic advisor to the Company. “I want to offer my gratitude, and my congratulations to Peter Cuneo on his retirement from the electro ...

Midea MASTER Series Refrigerators Midea MASTER Series Refrigerators BERLIN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- At Midea, we're committed to constantly innovating, elevating the performance of home appliances that enhance our everyday lives to be more efficient, effective and simply better. Therefore, we’re proud to showcase the latest in our lineup of home refrigerators across four product series here at IFA, with models featuring cutting-edge technologies including AI-powered cooling optimization and f ...

KENMORE, N.Y. and MIAMI, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced a new partnership with HealingMaps, the leading directory for ketamine, psychedelic-assisted therapy, and transcranial magnetic stimulation (“TMS”) clinics, and Advanced Behavioral Strategies (ABS). The collaboration co ...